miR‑140‑3p enhances cisplatin sensitivity and attenuates stem cell‑like properties through repressing Wnt/β‑catenin signaling in lung adenocarcinoma cells
- Shuoming Wu
- Haoran Wang
- Yinpeng Pan
- Xiangbao Yang
- Duoguang Wu
Affiliations: Department of Thoracic Surgery, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China, Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China, Department of Thoracic Surgery, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China
- Published online on: June 5, 2020 https://doi.org/10.3892/etm.2020.8847
Copyright: © Wu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Lung adenocarcinoma (LUAD) is the most predominant subtype of non‑small cell lung cancer (NSCLC) that is experiencing the fastest growth rate in incidence. Chemoresistance and the presence of cancer stem cells are considered to be the main obstacles preventing the successful treatment of patients with NSCLC, the molecular mechanism of which remains poorly understood. The present study aimed to investigate the effects of microRNA (miR)‑140‑3p on cisplatin sensitivity and stem cell‑like properties of LUAD cells. Analysis of publicly available data demonstrated that miR‑140‑3p expression was downregulated in LUAD, and positively associated with the overall survival rate of patients. In addition, transfection with the miR‑140‑3p mimic reduced LUAD cell viability and induced apoptosis following treatment with cisplatin whilst decreasing stem cell‑like properties. miR‑140‑3p overexpression was also found to attenuate cisplatin resistance and reduce stem cell‑like properties in LUAD cells by suppressing Wnt/β‑catenin signaling, all of which were reversed by the overexpression of β‑catenin. Taken together, results of the present study suggest miR‑140‑3p to be an effective therapeutic strategy for patients with LUAD.